TREATMENT PATTERNS AND CLINICAL OUTCOMES AMONG PATIENTS RECEIVING CDK4/6 INHIBITORS FOR HR+/HER2ADVANCED/METASTATIC BREAST CANCER IN A SINGLE-CENTRE, CANADIAN REAL-WORLD SETTING USING AI-EXTRACTED DATA

被引：0
|
作者：
Moulson, Ruth [1 ]
Feugere, Guillaume [2 ]
Moreira-Lucas, Tracy [2 ]
Dequen, Florence [2 ]
Weiss, Jessica [1 ]
Smith, Janet [3 ]
Brezden-Masley, Christine [3 ]
机构：
[1] Pentavere, Toronto, ON, Canada
[2] Pfizer Canada, Kirkland, PQ, Canada
[3] Mt Sinai Hosp, New York, NY USA
来源：
BREAST | 2023年 / 71卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO107
引用
收藏
页码：S51 / S51
页数：1
相关论文
共 50 条
  • [1] Real-World Treatment Patterns and Clinical Outcomes among Patients Receiving CDK4/6 Inhibitors for Metastatic Breast Cancer in a Canadian Setting Using AI-Extracted Data
    Moulson, Ruth
    Feugere, Guillaume
    Moreira-Lucas, Tracy S.
    Dequen, Florence
    Weiss, Jessica
    Smith, Janet
    Brezden-Masley, Christine
    CURRENT ONCOLOGY, 2024, 31 (04) : 2172 - 2184
  • [2] Real-World Experience with CDK4/6 Inhibitors for Metastatic HR+/HER2-Breast Cancer at a Single Cancer Center
    Knudsen, Erik S.
    Schultz, Emily
    Hamilton, Deanna
    Attwood, Kris
    Edge, Stephen
    O'Connor, Tracey
    Levine, Ellis
    Witkiewicz, Agnieszka K.
    ONCOLOGIST, 2022, 27 (08): : 646 - 654
  • [3] Real-world experience with CDK4/6 inhibitors for metastatic HR+/HER2-breast cancer at a single cancer center
    Milovic-Kovacevic, M.
    Bobic, S.
    Karaferic, A.
    Pavlovic, L.
    Matovic, M.
    Poparic-Bandjur, B.
    BREAST, 2023, 68 : S115 - S115
  • [4] Real-world experience with CDK4/6 inhibitors for HR+/HER2-metastatic breast cancer (MBC)
    Abdallah, H. M. A.
    Owoseni, Y. I.
    Sultan, A.
    Ahmed, S.
    Wood, J.
    Varadhan, B.
    Ayodele, O.
    ANNALS OF ONCOLOGY, 2023, 34 : S369 - S370
  • [5] Patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors: a real-world study in Italy
    Perrone, Valentina
    Dovizio, Melania
    Leogrande, Melania
    Tamma, Antonella
    Giovannitti, Massimo
    Buzzoni, Carlotta
    Esposti, Luca Degli
    BREAST CANCER MANAGEMENT, 2023, 12 (02)
  • [6] CDK4/6 inhibitors in advanced HR+/HER2-breast cancer - a multicenter real world data analysis
    Mueller, C.
    Kiver, V
    Solomayer, E-F
    Wagenpfeil, G.
    Neeb, C.
    Blohmer, J. U.
    Abramian, A., V
    Maass, N.
    Schuetz, F.
    Kolberg-Liedtke, C.
    Ralser, D. J.
    Rambow, A-C
    BREAST CARE, 2023, 18 (01) : 31 - 41
  • [7] Real-World Experience with CDK4/6 Inhibitors in the First-Line Palliative Setting for HR+/HER2-Advanced Breast Cancer
    Patel, Ram
    Mathews, John
    Hamm, Caroline
    Kulkarni, Swati
    Gupta, Rasna
    Opperman, Tarquin
    Chiong, John Dean
    Nasser, Abdullah
    CURRENT ONCOLOGY, 2025, 32 (01)
  • [8] Real-world experience with CDK4/6 inhibitors in the first-line palliative setting for HR+/HER2-advanced breast cancer
    Patel, Ram
    Nasser, Abdullah
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [9] Breast Cancer CDK4/6 Inhibitors in Patients with metastatic HR+/HER2-Breast Cancer
    Schmale, Ine
    ONCOLOGY RESEARCH AND TREATMENT, 2023, 46 (1-2)
  • [10] CDK4/6 inhibitors in HR+/HER2-advanced/metastatic breast cancer: a systematic literature review of real-world evidence studies
    Harbeck, Nadia
    Bartlett, Meaghan
    Spurden, Dean
    Hooper, Becky
    Zhan, Lin
    Rosta, Emily
    Cameron, Chris
    Mitra, Debanjali
    Zhou, Anna
    FUTURE ONCOLOGY, 2021, 17 (16) : 2107 - 2122
12345